The cGAS-STING pathway: Post-translational modifications and functional implications in diseases |
| |
| Institution: | 1. Institute of Medical Immunology, Affiliated Hospital of Jiangsu University, Zhenjiang, China;2. Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China;3. Department of Rheumatology, the Second People''s Hospital, China Three Gorges University, Yichang, China;4. Department of Rheumatology and immunology, Xiangya Hospital, Central South University, Changsha, China;5. Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong; Chongqing International Institute for Immunology, China;6. Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China;7. Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China;1. NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain;2. Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain;3. Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain;1. Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0367, USA;2. UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0367, USA;1. Center of Smart Laboratory and Molecular Medicine, School of Medicine, Chongqing University, Chongqing 400044, PR China;2. Department of Clinical Laboratory, The Second Hospital of Shandong University, 250033 Jinan, Shandong, PR China;3. Department of Oncology, Jiangjin Hospital, Chongqing University, Chongqing 402260, PR China;1. Centre of Reproduction, Development and Aging and Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Macau 999078, China;2. Brain Research Centre and Department of Biology, School of Life Science, Southern University of Science and Technology, 1088 Xueyuan Blvd, Nanshan District, Shenzhen, Guangdong Province 518055, China;3. Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 9112001, Israel;4. Anesthesia, Critical Care Medicine and Physiology, St. Michael’s Hospital, University of Toronto, Ontario, Canada;5. Institute for Global Food Security, School of Biological Sciences, Queen''s University Belfast, Belfast BT9 5DL, United Kingdom;6. Pharmacology, School of Pharmacy Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112002, Israel;1. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy;2. Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Tronto 10/A, 60020 Ancona, Italy |
| |
| Abstract: | Recent studies have illustrated the functional significance of DNA recognition in the activation of innate immune responses among a variety of diseases. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway has been found to be modulated by post-translational modifications and can regulate the immune response via type I IFNs. Accumulating evidence indicates a pivotal role of cGAS-STING signaling, being protective or pathogenic, in the development of diseases. Thus, a comprehensive understanding of the post-translational modifications of cGAS-STING pathway and their role in disease development will provide insights in predicting individual disease outcomes and developing appropriate therapies. In this review, we will discuss the regulation of the cGAS-STING pathway and its implications in disease pathologies, as well as pharmacologic strategies to target the cGAS-STING pathway for therapeutic intervention. |
| |
| Keywords: | CGAS STING Post-translational modifications Signaling pathway Disease treatment |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
